We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abiomed's Latest Regulatory Progress Boosts Impella Line
Read MoreHide Full Article
Abiomed Inc.’s flagship Impella product line shines bright on the receipt of pre-market approval from the FDA for its Impella RP heart pump. Notably, Impella RP is the only FDA-cleared percutaneous temporary ventricular support device available in the market.
The Impella RP System has been exclusively formulated to provide temporary right ventricular support to patients with acute right heart failure or decompensation. Its important to note that, the device does not involve any sort of surgical procedure for insertion. In fact, Impella RP provides more than four liters of blood per minute to provide hemodynamic support to patients.
Per management, the latest regulatory go ahead eradicates the risks associated with Right Ventricular Failure (RVF). These risks include increased mortality, longer lengths of stay in the intensive care unit and end-organ dysfunction.
We believe that robust demand for Impella products will continue to drive Abiomed’s top line over the long term. Notably, Impella line has other FDA-approved products like Impella 2.5, Impella CP and Impella 5.0. This business line is exclusively designed to treat patients in cardiogenic shock or undergoing elective and urgent percutaneous coronary interventions (PCI). Evidently, Impella heart pump’s global revenues grew a strong 30% in the last quarter.
Bottom Line
Lately, management at Abiomed has made significant investments in training and data collection procedures from Impella platform. The Impella line has been gaining prominence in the international ventricular-assist devices markets as well. The company’s continued progress in countries like Germany and Japan, leveraging on the Impella line, is worth a mention.
Data from Research And Markets suggests that the ventricular-assist devices global market is set to reach a worth of $2.8 billion by 2023. Meanwhile, the company faces stiff competition from organizations developing permanent heart assist products like Teleflex Inc. (TFX - Free Report) , Abbott Laboratories (ABT - Free Report) and Fresenius Medical Care (FMS - Free Report) .
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Image: Bigstock
Abiomed's Latest Regulatory Progress Boosts Impella Line
Abiomed Inc.’s flagship Impella product line shines bright on the receipt of pre-market approval from the FDA for its Impella RP heart pump. Notably, Impella RP is the only FDA-cleared percutaneous temporary ventricular support device available in the market.
The Impella RP System has been exclusively formulated to provide temporary right ventricular support to patients with acute right heart failure or decompensation. Its important to note that, the device does not involve any sort of surgical procedure for insertion. In fact, Impella RP provides more than four liters of blood per minute to provide hemodynamic support to patients.
Per management, the latest regulatory go ahead eradicates the risks associated with Right Ventricular Failure (RVF). These risks include increased mortality, longer lengths of stay in the intensive care unit and end-organ dysfunction.
We believe that robust demand for Impella products will continue to drive Abiomed’s top line over the long term. Notably, Impella line has other FDA-approved products like Impella 2.5, Impella CP and Impella 5.0. This business line is exclusively designed to treat patients in cardiogenic shock or undergoing elective and urgent percutaneous coronary interventions (PCI). Evidently, Impella heart pump’s global revenues grew a strong 30% in the last quarter.
Bottom Line
Lately, management at Abiomed has made significant investments in training and data collection procedures from Impella platform. The Impella line has been gaining prominence in the international ventricular-assist devices markets as well. The company’s continued progress in countries like Germany and Japan, leveraging on the Impella line, is worth a mention.
Data from Research And Markets suggests that the ventricular-assist devices global market is set to reach a worth of $2.8 billion by 2023. Meanwhile, the company faces stiff competition from organizations developing permanent heart assist products like Teleflex Inc. (TFX - Free Report) , Abbott Laboratories (ABT - Free Report) and Fresenius Medical Care (FMS - Free Report) .
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>